ELLE

Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

LEVERKUSEN, Germany - Biofrontera AG (DSE: B8F) announces todaythat it has received very positive results in the dose finding partof its phase IIb/III clinical trial started in autumn 2006. BF-200ALA, a gel that combines the active substance 5-aminolevulinic acid(ALA) with the nanoemulsion BF-200, was strongly and significantlysuperior to placebo in the treatment of actinic keratosis. BF-...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today released top-line findingsfrom its six month study of Proellex in the treatment ofendometriosis. This study, conducted in Europe, enrolled 39premenopausal women and has completed six months of dosing. Thestudy included three dose levels of Proellex(TM) as well as apositive control arm. The po...

Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data

CHAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- With enormousinvestments and the success of a pharmaceutical product at play,pharmaceutical firms need to develop effective strategies forcommunicating clinical trial results early. Companies that mastertheir communication planning and execution will gain a significantadvantage in the marketplace. According to research and consulting...

Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

Single-Dose Oral Ty800 Vaccine Immunogenic & Well-Toleratedin NIH-Sponsored Phase 1/2 Study NEEDHAM, MA (May 18, 2007) - AVANT Immunotherapeutics, Inc.(Nasdaq: AVAN) announced today positive preliminary results from aninvestigational double-blind, placebo-controlled Phase 1/2dose-escalating clinical trial of its typhoid fever vaccinecandidate, Ty800, in healthy volunteers. The...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

NEEDHAM, Mass.--(BUSINESS WIRE)--May 18, 2007 - AVANTImmunotherapeutics, Inc. (Nasdaq: AVAN) announced today positivepreliminary results from an investigational double-blind,placebo-controlled Phase 1/2 dose-escalating clinical trial of itstyphoid fever vaccine candidate, Ty800, in healthy volunteers. Theresearchers found the single-dose, oral vaccine to be welltolerated and immunogenic, wi...

Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke

NICE Appraisal Committee concludes that alteplase is clinicallyand cost effective INGELHEIM/Germany, 14 May 2007 – A new clinical appraisalpublished by the National Institute for Health and ClinicalExcellence (NICE) in the UK has recommended the use of alteplasefor the treatment of patients with acute ischaemic stroke, based onits clinical and cost effectiveness...

Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells

SAN CARLOS, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - CellerantTherapeutics today announced the publication of data suggestingthat established autoimmune disease can be reversed or stabilizedby the transplantation of purified allogeneic (donated)hematopoietic (blood forming) stem cells (HSC) in a mouse study ofSystemic Lupus Erythematosus (SLE). Subjects that underwent thisprocedure exhibited...

Repros' Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) announced final results of a U.S.Phase 2 study of Proellex(TM), an oral drug being developed torelieve symptoms of uterine fibroids. This study suggests thattreatment with Proellex results in a statistically highlysignificant improvement in symptoms associated with uterinefibroids and is generally w...

Ace Biosciences, Ace393, the World's First Commercial Vaccine for Travellers' Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Ace Biosciences, Ace393, the World's First Commercial Vaccinefor Travellers' Diarrhoea Caused by Campylobacter SuccessfullyCompletes Phase I Clinical Trials Trial confirms good safety profile and strong immunogenicity ODENSE, Denmark, March 28, 2007 -ACE BioSciences A/S, theinfectious diseases company is pleased to announce the successfulcompletion of Phase I clinical t...